Oestradiol Benzoate may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Estradiol 3-benzoate (a derivative of Estradiol) is reported as an ingredient of Oestradiol Benzoate in the following countries:
International Drug Name Search
Guttanotte may be available in the countries listed below.
Flunitrazepam is reported as an ingredient of Guttanotte in the following countries:
International Drug Name Search
Rec.INN
N02AB01
0000469-79-4
C15-H21-N-O2
247
Opioid analgesic
1-Propanone, 1-[4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl]-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Suboxone is a brand name of buprenorphine/naloxone, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Suboxone available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Suboxone. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Calcio 20 Fuerte may be available in the countries listed below.
Calcium Phosphate is reported as an ingredient of Calcio 20 Fuerte in the following countries:
Colecalciferol is reported as an ingredient of Calcio 20 Fuerte in the following countries:
International Drug Name Search
The following drugs and medications are in some way related to, or used in the treatment of Influenza Prophylaxis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
In the US, Prax (pramoxine topical) is a member of the drug class topical anesthetics and is used to treat Anal Itching, Pain and Pruritus.
US matches:
Pramocaine hydrochloride (a derivative of Pramocaine) is reported as an ingredient of Prax in the following countries:
International Drug Name Search
Rec.INN
N04BC08
0003605-01-4
C16-H18-N4-O2
298
Treatment of Parkinson's disease: Dopaminergic
Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Treating athlete's foot, jock itch, or ringworm and relieving the itching, scaling, burning, and discomfort due to those conditions. It may also be used for other conditions as determined by your doctor.
Desenex Spray is an antifungal. It works by weakening the fungal cell membrane, which kills the fungus.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Desenex Spray. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Desenex Spray. Because little, if any, of Desenex Spray is absorbed into the blood, the risk of it interacting with another medicine is low.
This may not be a complete list of all interactions that may occur. Ask your health care provider if Desenex Spray may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Desenex Spray as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Desenex Spray.
All medicines may cause side effects, but many people have no, or minor, side effects. When used in small doses, no COMMON side effects have been reported with this product. Seek medical attention right away if any of these SEVERE side effects occur:
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); irritation.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Store Desenex Spray at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Avoid temperatures above 120 degrees F (49 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Desenex Spray out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Desenex Spray. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Ciprobac may be available in the countries listed below.
Ciprofloxacin is reported as an ingredient of Ciprobac in the following countries:
Ciprofloxacin lactate (a derivative of Ciprofloxacin) is reported as an ingredient of Ciprobac in the following countries:
International Drug Name Search
Foucacillin may be available in the countries listed below.
Cefuroxime axetil (a derivative of Cefuroxime) is reported as an ingredient of Foucacillin in the following countries:
International Drug Name Search
Rantaksym may be available in the countries listed below.
Cefotaxime sodium salt (a derivative of Cefotaxime) is reported as an ingredient of Rantaksym in the following countries:
International Drug Name Search
Generic Name: oxymetazoline nasal (ox ee me TAZ oh leen)
Brand Names: Afrin, Afrin Nasal Sinus, Allerest 12 Hour Nasal Spray, Duramist Plus, Duration, Four-Way Nasal Spray, Genasal, Neo-Synephrine 12 Hour, Nostrilla, NRS Nasal, NTZ Long Acting Nasal, Oxyfrin, Oxymeta-12, Sinarest Nasal, Sinex Long-Acting, Twice-A-Day
Oxymetazoline is a decongestant. It works by constricting (shrinking) blood vessels (veins and arteries) in your body. The nasal formulation acts directly on the blood vessels in your nasal tissues. Constriction of the blood vessels in your nose and sinuses leads to drainage of these areas and a decrease in congestion.
Oxymetazoline nasal is used to treat congestion associated with allergies, hay fever, sinus irritation, and the common cold.
Oxymetazoline nasal may also be used for purposes other than those listed in this medication guide.
Do not use oxymetazoline nasal for longer than 3 to 5 days. Longer use could cause damage to your nasal tissue and lead to chronic congestion. If your symptoms do not improve, see your doctor.
Before taking this medication, tell your doctor if you have
high blood pressure;
any type of heart disease, hardening of the arteries, or irregular heart beats;
thyroid problems;
diabetes;
glaucoma or increased pressure in the eye;
an enlarged prostate or difficulty urinating; or
liver or kidney disease.
You may not be able to use oxymetazoline nasal, or you may require a lower dose or special monitoring during your therapy if you have any of the conditions listed above.
Use oxymetazoline nasal exactly as directed by your doctor, or follow the instructions that accompany the package. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.
To apply the nasal spray, keep your head upright, spray, then sniff hard for a few minutes after administering a dose.
To apply the nasal drops, lie on a bed on your back with your head hanging over the edge. Insert the drops and remain in this position for several minutes. Gently turn your head from side to side.
Do not allow the tip of the container to touch the inside of your nose or any other surface. This spreads the infection.
Also, to prevent the spread of infection, do not share this medication with anyone else.
Discard this medication bottle after use. Do not save it for reuse.
Do not use oxymetazoline nasal for longer than 3 to 5 days. Longer use could cause damage to your nasal tissue and lead to chronic congestion. If your symptoms do not improve, see your doctor.
Store oxymetazoline nasal at room temperature away from moisture and heat.
Use the missed dose as soon as you remember. However, if it is almost time for your next regularly scheduled dose, skip the missed dose and use the next one as directed. Do not use a double dose of this medication.
Symptoms of an oxymetazoline nasal overdose include extreme tiredness, sweating, dizziness, a slow heartbeat, and coma.
If you experience any of the following serious side effects, stop using oxymetazoline nasal and seek emergency medical attention:
an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
seizures;
unusual behavior or hallucinations; or
an irregular or fast heartbeat.
More commonly, you may experience some sneezing or burning, stinging, dryness, or irritation of the nose. These side effects are usually mild and temporary.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.
Although drug interactions between topical nasal decongestants and drugs taken by mouth are not expected, they can occur. Rarely, oxymetazoline nasal may interact with the following medicines:
furazolidone (Furoxone);
guanethidine (Ismelin);
indomethacin (Indocin);
methyldopa (Aldomet);
bromocriptine (Parlodel);
caffeine in cola, tea, coffee, chocolate and other products;
theophylline (Theo-Dur, Theochron, Theolair, others);
Drugs other than those listed here may also interact with oxymetazoline nasal. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.
See also: Oxyfrin side effects (in more detail)
UK matches:
Flecainide Acetate (BANM, USAN) is known as Flecainide in the US.
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| SPC | Summary of Product Characteristics (UK) |
| USAN | United States Adopted Name |
Glandin N may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Dinoprost is reported as an ingredient of Glandin N in the following countries:
International Drug Name Search
Buspirone Sandoz may be available in the countries listed below.
Buspirone hydrochloride (a derivative of Buspirone) is reported as an ingredient of Buspirone Sandoz in the following countries:
International Drug Name Search
Nikofrenon may be available in the countries listed below.
Nicotine is reported as an ingredient of Nikofrenon in the following countries:
International Drug Name Search
Mecanyl may be available in the countries listed below.
Glucosamine sulfate (a derivative of Glucosamine) is reported as an ingredient of Mecanyl in the following countries:
International Drug Name Search
Midon may be available in the countries listed below.
Midodrine hydrochloride (a derivative of Midodrine) is reported as an ingredient of Midon in the following countries:
International Drug Name Search
Cefotaxim-ratiopharm may be available in the countries listed below.
Cefotaxime sodium salt (a derivative of Cefotaxime) is reported as an ingredient of Cefotaxim-ratiopharm in the following countries:
International Drug Name Search
LevoCar retard may be available in the countries listed below.
Carbidopa is reported as an ingredient of LevoCar retard in the following countries:
Levodopa is reported as an ingredient of LevoCar retard in the following countries:
International Drug Name Search
Permit Ungeziefershampoo may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Permethrin is reported as an ingredient of Permit Ungeziefershampoo in the following countries:
International Drug Name Search
Dexagalen may be available in the countries listed below.
Dexamethasone 21-(disodium phosphate) (a derivative of Dexamethasone) is reported as an ingredient of Dexagalen in the following countries:
International Drug Name Search
Diky may be available in the countries listed below.
Diclofenac is reported as an ingredient of Diky in the following countries:
International Drug Name Search
Asýran may be available in the countries listed below.
Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Asýran in the following countries:
International Drug Name Search
Escopolamina N-Butyl Bromuro may be available in the countries listed below.
Scopolamine butylbromide (a derivative of Scopolamine) is reported as an ingredient of Escopolamina N-Butyl Bromuro in the following countries:
Scopolamine hydrobromide (a derivative of Scopolamine) is reported as an ingredient of Escopolamina N-Butyl Bromuro in the following countries:
International Drug Name Search
Sapimol may be available in the countries listed below.
Ipratropium Bromide monohydrate (a derivative of Ipratropium Bromide) is reported as an ingredient of Sapimol in the following countries:
Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Sapimol in the following countries:
International Drug Name Search
Vincristinsulfat Hexal may be available in the countries listed below.
Vincristine sulfate (a derivative of Vincristine) is reported as an ingredient of Vincristinsulfat Hexal in the following countries:
International Drug Name Search
Kayexalate Calcium may be available in the countries listed below.
Polystyrene Sulfonic Acid calcium salt (a derivative of Polystyrene Sulfonic Acid) is reported as an ingredient of Kayexalate Calcium in the following countries:
International Drug Name Search
Clobetamil may be available in the countries listed below.
Clobetasol 17α-propionate (a derivative of Clobetasol) is reported as an ingredient of Clobetamil in the following countries:
International Drug Name Search
Pentoxifilin may be available in the countries listed below.
Pentoxifylline is reported as an ingredient of Pentoxifilin in the following countries:
International Drug Name Search
Equiworm F may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Fenbendazole is reported as an ingredient of Equiworm F in the following countries:
International Drug Name Search
Megafer may be available in the countries listed below.
Ferrous Gluconate is reported as an ingredient of Megafer in the following countries:
International Drug Name Search
Glidan may be available in the countries listed below.
Gliclazide is reported as an ingredient of Glidan in the following countries:
International Drug Name Search
Generic Name: Oxandrolone
Class: Androgens
ATC Class: A14AA
VA Class: HS100
Chemical Name: 17β-Hydroxy-17-αmethyl-2-oxa-5α-androstan-3-one
Molecular Formula: C19H30O3
CAS Number: 53-39-4
Peliosis hepatis, a condition in which the liver contains blood-filled cysts, reported with androgen therapy.1 4 30 31 34 May present with minimal hepatic dysfunction,1 4 34 or effects may not be apparent until complicated by life-threatening liver failure or rupture of the cysts resulting in intra-abdominal hemorrhage.1 4 5 7 31 34 (See Hepatic Effects under Cautions.)
Discontinuance of androgen therapy usually results in resolution of liver lesions.1 4 32 34
Liver cell tumors reported with androgen therapy.1 4 5 7 30 31 34 Tumors are usually benign and androgen dependent; hepatocellular carcinoma, sometimes fatal, also reported.1 4 5 7 34
Liver cell tumors associated with androgens are more vascular than other hepatic tumors; hepatic effects may not be apparent until complicated by life-threatening intra-abdominal hemorrhage.1 4 5 34
Discontinuance of androgen therapy often but not always results in regression or cessation of progression of the tumor.1 4 5 34
May markedly alter serum lipoprotein concentrations; decreased HDL- and increased LDL-cholesterol reported with androgen therapy.1 4 30 31 34 Consider increased risk of cardiovascular disease (e.g., atherosclerosis and CAD).1 4 31 34 (See Lipid Abnormalities under Cautions.)
Synthetic androgenic anabolic steroid hormone.1 4
Adjunct to conventional therapy to promote weight gain in individuals who experience weight loss following extensive surgery, chronic infections (e.g., HIV-associated wasting syndrome; designated an orphan drug by FDA for this use),3 or severe trauma (e.g., burns, spinal cord injury).1 5 17 19 22 32
Adjunct to conventional therapy for management of unexplained weight loss.1
Adjunct to conventional therapy to offset protein catabolism (e.g., muscle wasting, muscle pain or weakness, delayed wound healing, atrophy of protein matrix of bone) associated with long-term corticosteroid therapy.1 4 20 21 33
Labeled for the symptomatic treatment of bone pain accompanying osteoporosis.1 4 23
Androgens have been misused and abused by athletes, bodybuilders, weight lifters, and others to enhance athletic performance or physique†.6 7 8 9 10 32
Medical and sports experts (e.g., International Olympic Committee) consider such use to be inappropriate and unacceptable because of known adverse effects and potential long-term sequelae.9 Such misuse by athletes is contrary to rules and ethical principles of athletic competition.7 8 9 10
Manufacturer states that androgens have not been shown to enhance athletic performance.1
Individualize dosage and duration of therapy carefully according to individual requirements, response, and tolerance.1 4 Use the minimum effective dosage; intended for intermittent use.1 4 22
Administer orally 2–4 times daily in adults.1 4
≤0.1 mg/kg daily for 2–4 weeks.1 4 Repeat course of therapy intermittently as needed to maintain weight.1 4 32
Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response (i.e., slowing or cessation of weight loss).1 4 32 A longer period of treatment is necessary to regain lost weight, especially if ongoing catabolic stressors are present.32
Higher than recommended dosage of 0.1 mg/kg twice daily for 5 days to 12 months† has been evaluated in pediatric patients with burns.1 4 5 16 17 18 32
≤0.1 mg/kg daily.1 4 Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response.1 4 32 Repeat course of therapy intermittently as needed.1 4 32
2.5–20 mg daily in 2–4 divided doses for 2–4 weeks.1 4 Repeat course of therapy intermittently as needed to maintain weight.1 4 32
Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response (i.e., slowing or cessation of weight loss).1 4 32 A longer period of treatment is necessary to regain lost weight, especially if ongoing catabolic stressors are present.32 Continuous administration for 3–4 months has been evaluated in patients with HIV-associated wasting syndrome.5 19
2.5–20 mg daily in 2–4 divided doses.1 4 Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response.1 4 32 Repeat course of therapy intermittently as needed.1 4 32
2.5–20 mg daily in 2–4 divided doses.1 4 Manufacturer states that a 2- to 4-week course of therapy usually is adequate to observe a response.1 4 Repeat course of therapy intermittently as needed.1 4
5 mg twice daily for 2–4 weeks recommended.1 Repeat course of therapy intermittently as needed.1 (See Geriatric Use under Cautions.)
Males with breast cancer or known or suspected prostate cancer.1 4
Women with hypercalcemia associated with metastatic breast cancer.1 4 (See Hypercalcemia under Cautions.)
Known or suspected pregnancy.1 4 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)
Nephrosis.1 4
Hypercalcemia.1 4 (See Hypercalcemia under Cautions.)
May cause fetal harm; potential for virilization of fetus.1 4
Fetotoxicity, embryotoxicity, infertility, and virilization of female offspring demonstrated in animals.1 4
Potentially serious and/or life-threatening adverse hepatic effects (e.g., peliosis hepatis, hepatic adenomas, hepatocellular carcinoma) associated with prolonged use of high dosages of androgens.5 6 7 9 10 22 (See Boxed Warning.)
If cholestatic hepatitis with jaundice occurs, or if liver function test results become abnormal during therapy, discontinue oxandrolone and investigate etiology of these disorders.1 4 Drug-induced jaundice usually is reversible after discontinuance of drug.1 4
Monitor liver function periodically.1 4 17 22
Possible hypercalcemia resulting from osteolysis in women with metastatic carcinoma of the breast.1 4 Monitor urine and serum calcium concentrations frequently during the course of androgen therapy in women with metastatic breast cancer.1 4 30
If hypercalcemia occurs, discontinue the drug.1 4 (See Contraindications under Cautions.)
Edema, with or without CHF, possible as a result of sodium and water retention and may be a serious complication in patients with preexisting cardiac, renal, or hepatic disease.1 4 30 (See Geriatric Use under Cautions.)
Potential for serious adverse effects (e.g., increased aggression,6 7 8 10 13 22 antisocial behavior,6 7 manic episode,6 22 depression,9 changes in libido,6 7 8 9 10 22 increased risk of cardiovascular disease,6 7 8 9 hepatotoxicity6 7 8 9 10 ) associated with misuse and abuse of androgens (see Misuse and Abuse under Uses); oxandrolone preparations currently subject to control under the Federal Controlled Substances Act of 1970, as amended by the Anabolic Steroids Control Act of 1990 and 2004, as schedule III (C-III) drugs.11 32
Virilization, including baldness, clitoral enlargement, deepening of voice, hirsutism, and menstrual irregularities, may occur in females.1 4 5 6 9 13
Monitor women receiving oxandrolone therapy for signs of virilization.1 4 If virilization occurs, promptly discontinue therapy.1 4 Some changes may not be reversible (e.g., clitoral enlargement, voice changes) after discontinuance of the drug; concomitant use of estrogen with androgens does not prevent these effects.1 4 6 7 32
Possible polycythemia, especially with high dosages of androgens.1 4 30 Perform periodic hemoglobin and hematocrit determinations in patients receiving high dosages of androgens.1 4 30
Anabolic steroids may suppress clotting factors II, V, VII, and X and prolong PT.1 4 (See Specific Drugs and Laboratory Tests under Interactions.)
Androgens may increase LDL-cholesterol and decrease HDL-cholesterol concentrations; consider the increased risk for cardiovascular disease.1 4 5 6 7 10 12 13 19 22 32 Lipid concentrations return to baseline values approximately 1 month after discontinuance of androgen therapy.22
Use with caution in patients with cardiovascular disease or risk factors for cardiovascular disease.1 4 Determine serum lipid concentrations periodically; adjust therapy accordingly.1 4
Category X.1 4 (See Fetal/Neonatal Morbidity and Mortality and also Contraindications under Cautions.)
Not known whether oxandrolone is distributed into milk.1 4 Discontinue nursing or the drug.1 4
May accelerate bone maturation without producing compensatory gain in linear growth, possibly resulting in compromised adult stature.1 4 10 The younger the child, the greater the risk of the drug compromising final mature stature.1 4
Use with extreme caution in children and only under the supervision of a specialist who is aware of the adverse effects of oxandrolone on bone maturation.1 4 Perform radiographic examination of the left hand and wrist every 6 months to determine rate of bone maturation and to assess the effect of treatment on epiphyseal centers.1 4
Possible increased risk of developing prostatic hypertrophy and prostate cancer during androgen therapy.1 4 30
Response in patients ≥65 years of age does not appear to differ from that in younger adults.1 Increased sensitivity to fluid retention and increases in hepatic transaminase values reported, particularly in geriatric women.1 Use lower dosage to minimize adverse effects.1 (See Geriatric Patients under Dosage and Administration.)
Elevated aminotransferases (ALT, AST),1 4 5 13 17 19 lipid abnormalities (e.g., decreased HDL cholesterol concentrations).1 4 5 13 19
Drug or Test | Interaction | Comments |
|---|---|---|
Anticoagulants, oral | May potentiate action of oral anticoagulants and decrease anticoagulant requirements1 4 22 24 26 32 Increases AUC and half-life of warfarin; minor bleeding reported;1 4 80-85% decrease in warfarin dosage (from a mean of 6.13 mg daily to a mean of 1.13 mg daily) were needed to maintain target INR of 1.5 in one study1 4 32 | Monitor PT or INR when oxandrolone therapy is initiated or discontinued in patients receiving oral anticoagulants and adjust anticoagulant dosage as needed1 4 32 Initial anticoagulant dosage may be substantially lower in patients receiving oxandrolone32 Monitor for signs and symptoms of occult bleeding1 4 |
Antidiabetic agents, oral (sulfonylureas) | Possible inhibition of sulfonylurea metabolism1 4 32 | Use concomitantly with care6 |
Corticotropin (ACTH) and corticosteroids | May exacerbate edema1 4 | Consider possibility of interaction before use13 |
Tests for thyroid function | Possible decreased thyroxine-binding globulin concentrations, resulting in decreased total serum thyroxine (T4) concentrations and increased resin uptake of triiodothyronine (T3) and T41 4 16 Free thyroid hormone concentrations remain unchanged1 4 May decrease protein-bound iodine (PBI) concentrations and radioactive iodine uptake1 4 |
Well absorbed after oral administration, with peak serum concentrations attained in approximately 1 hour.5 13
95%.5 13
Partially metabolized via sulfation to 17-epioxandrolone; other metabolites also identified.5 13 14 25 27 28
Excreted principally in urine as unchanged and unconjugated oxandrolone (28%).5 25 27
Biphasic; distribution half-life is 30 minutes and elimination half-life is approximately 10.4 hours in adults.1 5 25
In geriatric individuals, elimination half-life is 13.3 hours.1
20–25°C.4
Produces marked anabolic activity and relatively few androgenic effects.5 6 7 13 14 22
Produces retention of nitrogen,5 7 13 17 22 increases protein anabolism and amino acid utilization, and decreases urinary calcium concentrations.2 5 13 16 18 23
Increases lean body mass, body cell mass, and muscle strength.7 9 16 17 18 19 20 22
Increases bone mineral density and content.5 13 16 22
Inhibits protein catabolism induced by corticosteroids.5 6 8 17 22
Androgens stimulate production of erythrocytes, apparently by enhancing production of erythropoietin.22 (See Hematologic Effects under Cautions.)
Inhibits release of endogenous testosterone via feedback inhibition of pituitary luteinizing hormone (LH).1 4 7 8 10 19 22 32
Large doses of androgens may suppress spermatogenesis.1 4 6 7 8 9 22
Risk of virilization in females.1 2 4 6 Advise female patients to contact their clinician if they notice hoarseness, acne, menstrual changes, baldness, genital changes, or growth of facial hair.1 2 4
Risk of priapism; importance of males informing clinicians if too frequent or persistent penile erections occur.1 4
Advise male patients to contact their clinician if they notice new or worsening acne.1 4
Importance of periodic assessments to determine rate of bone maturation in pediatric patients.1 4
Importance of informing clinician if nausea, vomiting, changes in skin color, or ankle swelling occurs.1 4
Risk of potential liver toxicity and/or lipid abnormalities (e.g., increased LDL-cholesterol concentrations and decreased HDL-cholesterol concentrations.1 4 Importance of regular laboratory monitoring of liver function and cholesterol concentrations.1 4
Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.1 4
Importance of informing clinician of existing or contemplated concomitant therapy, including prescription (e.g., warfarin, antidiabetic medications) and OTC drugs and herbal supplements, as well as any concomitant illnesses.1 4
Importance of informing patients of other important precautionary information.1 4 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Oxandrolone is subject to control under the Federal Controlled Substances Act of 1970, as amended by the Anabolic Steroids Control Act of 1990 and 2004, as a schedule III (C-III) drug.11
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Tablets | 2.5 mg | Oxandrin ( C-III; scored) | Savient |
Oxandrolone Tablets ( C-III; scored) | ||||
10 mg | Oxandrin ( C-III) | Savient | ||
Oxandrolone Tablets ( C-III) |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Oxandrin 10MG Tablets (SAVIENT PHARMACEUTICALS INC.): 30/$822.73 or 60/$1621.34
Oxandrin 2.5MG Tablets (SAVIENT PHARMACEUTICALS INC.): 30/$249.24 or 90/$725.97
Oxandrolone 10MG Tablets (SANDOZ): 30/$535.96 or 90/$1577.85
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions April 2010. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
1. Savient Pharmaceuticals. Oxandrin (oxandrolone) tablets prescribing information. East Brunswick, NJ; 2006 Jan.
2. AHFS consumer medication information. Oxandrolone. Bethesda, MD: American Society of Health-System Pharmacists; 2004 Oct 1. Available from website. Accessed 2008 Mar 7.
3. Food and Drug Administration. List of orphan designations and approvals. Rockville, MD; 2007 Oct 4. From FDA website. Accessed 2008 Mar 7.
4. Par Pharmaceutical Companies. Oxandrolone tablets prescribing information. Spring Valley, NY; 2007 Mar 3.
5. Orr R, Singh MF. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs. 2004; 64:725-50. [PubMed 15025546]
6. Kam PCA, Yarrow M. Anabolic steroid abuse: physiological and anaesthetic considerations. Anaesthesia. 2005; 60:685-92. [PubMed 15960720]
7. American College of Sports Medicine. Position stand on the use of anabolic-androgenic steroids in sports. Med Sci Sports Exerc. 1987; 19:534-9. [PubMed 3316907]
8. Committee on Sports Medicine and Fitness, American Academy of Pediatrics. Adolescents and anabolic steroids: a subject review. Pediatrics. 1997; 99:904-8. [PubMed 9190555]
9. Council on Scientific Affairs, American Medical Association. Medical and nonmedical uses of anabolic-androgenic steroids. JAMA. 1990; 264:2923-7. [IDIS 274793] [PubMed 2232088]
10. Council on Scientific Affairs, American Medical Association. Drug abuse in athletes: anabolic steroids and human growth hormone. JAMA. 1988; 259:1703-5. [IDIS 239600] [PubMed 3278150]
11. Drug Enforcement Administration (DEA), Department of Justice. Implementation of the Anabolic Steroid Control Act of 2004. Final rule. [21 CFR Part 1300 and 1308] Fed Regist. 2005; 70:74653-8.
12. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical practice guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients—2002 update. Endocr Pract. 2002; 8:440-56. [PubMed 15260010]
13. Akyurek M, Dunn RM. Oxandrolone. Plast Reconstr Surg. 2006; 118:791-4. [PubMed 16932191]
14. Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem. 1996; 42:1001-20.
16. Przkora R, Jeschke MG, Barrow RE et al. Metabolic and hormonal changes in severely burned children receiving long-term oxandrolone treatment. Ann Surg. 2005; 242:384-91. [PubMed 16135924]
17. Jeschke MG, Finnerty CC, Suman OE et al. The effect of oxandrolone on the endocrinologic, inflammatory, and hypermetabolic reponses during the acute phase postburn. Ann Surg. 2007; 246:351-62. [PubMed 17717439]
18. Wolf SE, Thomas SJ, Dasu MR et al. Improved net protein balance, lean mass, and gene expression changes with oxandrolone treatment in the severely burned. Ann Surg. 2003; 237:801-11. [PubMed 12796576]
19. Grunfeld C, Kotler DP, Dobs A et al. Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr. 2006; 41:304-14. [PubMed 16540931]
20. Kravetz JD, Lee C, Dieterich DT. Oxandrolone use in Crohn’s disease. Am J Gastroenterol. 1997; 92:2330-1. Letter [PubMed 9399787]
21. Dickerman RD, Joseph AM, Bennett MT. Corticosteroid-induced myopathy in spinal cord injury patients: a role for anticatabolic agents? Spinal Cord. 2006; 44:263-4. Letter
22. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther. 2001; 23:1355-90. [PubMed 11589254]
23. Riggs BL, Jowsey J, Kelly PJ et al. Studies on pathogenesis and treatment in postmenopausal and senile osteoporosis. Clin Endocrinol Metab. 1973; 2:317-32. [PubMed 4373194]
24. Bristol-Myers Squibb. Coumadin (warfarin sodium) tablets crystalline and Coumadin (warfarin sodium) for injection prescribing information. Princeton, NJ; 2007 Aug.
25. Massé R, Bi H, Ayotte C et al. Studies on anabolic steroids II—Gas chromatographic/mass spectrometric characterization of oxandrolone urinary metabolites in man. Biomed Environ Mass Spectrom. 1989; 18:429-38.
26. Koller EA, Wei X, Johnson TE. Oxandrolone steroid use and impaired coagulation. Arch Intern Med. 2006; 166:125. Letter. [PubMed 16401821]
27. Bi H, Massé R. Studies on anabolic steroids—12. Epimerization and degradation of anabolic 17β-sulfate-17α-methyl steroids in human: qualitative and quantitative GC/MS analysis. J Steroid Biochem Molec Biol. 1992; 42:533-46. [PubMed 1616883]
28. Gonzalez FJ, Tukey RH. Drug metabolism. In: Brunton L, Lazo JS, Parker KL, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006:82.
29. August D, Teitelbaum D, Albina J et al. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. Section XI: Specific guidelines for disease—adults. JEPN. 2002; 26:61S-96SA.
30. ICN Pharmaceuticals. Android (methyltestosterone) capsules prescribing information. Costa Mesa, CA; 2001 Sep.
31. Upsher-Smith Laboratories. Androxy (fluoxymesterone) tablets prescribing information. Minneapolis, MN; 2006 May.
32. Savient Pharmaceuticals, East Brunswick, NJ: Personal communication
33. AHFS drug information 2008. McEvoy GK, ed. Corticosteroids general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2008:3088.
34. Alaven Pharmaceutical. Anadrol (oxymetholone) prescribing information. Marietta, GA; 2006 Dec.
Nifedipine AccordHealthcare may be available in the countries listed below.
Nifedipine is reported as an ingredient of Nifedipine AccordHealthcare in the following countries:
International Drug Name Search
Pompaton may be available in the countries listed below.
Famotidine is reported as an ingredient of Pompaton in the following countries:
International Drug Name Search
In the US, Daranide (dichlorphenamide systemic) is a member of the drug class carbonic anhydrase inhibitors and is used to treat Glaucoma and Glaucoma/Intraocular Hypertension.
US matches:
Diclofenamide is reported as an ingredient of Daranide in the following countries:
International Drug Name Search
Suganril may be available in the countries listed below.
Piroxicam is reported as an ingredient of Suganril in the following countries:
International Drug Name Search
Galazolin may be available in the countries listed below.
Xylometazoline is reported as an ingredient of Galazolin in the following countries:
Xylometazoline hydrochloride (a derivative of Xylometazoline) is reported as an ingredient of Galazolin in the following countries:
International Drug Name Search
Insulatard may be available in the countries listed below.
UK matches:
Insulin Injection, Soluble human (a derivative of Insulin Injection, Soluble) is reported as an ingredient of Insulatard in the following countries:
Insulin, Isophane human (a derivative of Insulin, Isophane) is reported as an ingredient of Insulatard in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Soflet may be available in the countries listed below.
Alcloxa is reported as an ingredient of Soflet in the following countries:
International Drug Name Search
Cefotaxime Panpharma may be available in the countries listed below.
Cefotaxime is reported as an ingredient of Cefotaxime Panpharma in the following countries:
International Drug Name Search
